Maternal HIV viral load testing during pregnancy and postpartum care in Gauteng Province, South Africa by Moyo, F et al.
469       May 2021, Vol. 111, No. 5
RESEARCH
Maternal viral load (VL) is closely associated with the risk of 
mother-to-child transmission (MTCT) of HIV.[1-3] Frequent and 
timely VL testing of pregnant and breastfeeding women living 
with HIV (WLHIV) is therefore critical to prevent MTCT, because 
there is limited time for identifying women with high VLs and 
instituting interventions, such as switching regimens and/or 
intensifying adherence support, to ensure VL suppression. The South 
African (SA) Prevention of Mother-to-Child Transmission of HIV 
(PMTCT) programme has evolved to enable universal HIV testing 
and antiretroviral therapy (ART) coverage in the public sector. For 
monitoring treatment response, the PMTCT guidelines since 2015 
have recommended a VL test at the first antenatal care (ANC) visit for 
WLHIV already on ART, irrespective of when the last VL was done. [4] 
For WLHIV newly diagnosed with HIV during pregnancy, a VL is 
recommended after 3 months of ART use. In both groups, 6-monthly 
VL monitoring follows throughout pregnancy and the breastfeeding 
period. In November 2019, the guidelines were revised to include a 
VL test at delivery for all WLHIV, and the VL threshold for instituting 
intensified adherence support and/or regimen changes was lowered 
from ≥1 000 to ≥50 copies/mL.[5]
Despite the existence of a robust PMTCT policy framework, minimal 
attention has been placed on maternal VL monitoring during 
pregnancy and the postpartum period in SA.[2] Previous reports 
have found VL testing coverage as low as 30% during pregnancy or 
the breastfeeding period,[6] with frequent disengagement from care 
during the postpartum period, particularly among WLHIV newly 
initiating ART during pregnancy.[7,8] Furthermore, ~20% of maternal 
VLs were ≥1 000 copies/mL during antenatal and postpartum care,[9] 
while up to 37% of pregnant WLHIV have a VL ≥50 copies/mL at 
delivery in the public health sector.[10-12] The high proportions of 
unsuppressed maternal VLs have important implications for vertical 
transmission, as elimination of mother-to-child transmission of 
HIV (eMTCT) requires sustained suppression of the maternal VL 
at <50  copies/mL throughout pregnancy, delivery and the breast-
feeding period. The foregoing suggests that the programme is far 
from achieving the Joint United Nations Programme on HIV and 
AIDS (UNAIDS) 90-90-90 and eMTCT targets.[13,14]
SA’s public health sector provides routine HIV VL testing via a 
well-established, centralised laboratory network that is accessible 
to 4 300 ANC facilities nationally.[15] However, delays exist from 
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specimen collection to testing and ultimately 
the return of results to patients.[2] Point-
of-care (PoC) HIV VL testing has been 
proposed as a game changer for fast-tracking 
eMTCT in SA. PoC VL testing can reduce 
gaps along the VL monitoring cascade by 
accelerating the return of results to patients 
and facilitating prompt clinical management 
in cases with elevated maternal VLs.[16-18] 
Previous reports suggest that PoC HIV 
VL technologies have a place in routine 
settings in SA. However, scale-up needs 
to complement existing laboratory-based 
systems and address site-specific health 
system level factors.[15]
Objectives
To review compliance of VL testing with 
national guidelines and suppression rates 
during the antenatal period and up to 
9 months postpartum among WLHIV who 
received a PoC HIV VL test at delivery at 
four tertiary hospitals in Gauteng Province, 
SA.
Methods
Between June 2018 and February 2020, PoC 
HIV VL testing was piloted at four tertiary 
obstetric units in Gauteng – three in the 
City of Johannesburg and one in Tshwane 
District. All pregnant WLHIV presenting at 
labour or postnatal wards were eligible for 
PoC HIV VL testing using Xpert HIV-1 VL 
(Cepheid, USA). Specimen collection was 
performed by nurses and doctors as part of 
routine care, while testing was performed 
by trained PoC operators on site. Testing 
was performed on weekdays between 08h00 
and 16h00. No clinical details, such as time 
of first HIV diagnosis, PMTCT regimen or 
ANC attendance, were recorded. All women 
who received a PoC HIV VL test at delivery 
were included in the study. For each PoC HIV 
VL that was performed, a corresponding 
sample was sent for routine testing to 
the National Health Laboratory Service 
(NHLS), with the two samples sharing the 
same laboratory barcode. Previous and 
subsequent HIV VL tests associated with the 
same patient, as per the NHLS’s Corporate 
Data Warehouse (CDW)-generated unique 
patient identifier, were extracted from the 
NHLS CDW. HIV VL test data extracted 
included VLs performed up to 9 months 
before and after the delivery HIV VL. VLs 
performed up to 9 months before delivery 
were used as a proxy for VL monitoring 
during the antenatal period. Record linkage 
in the NHLS CDW relied on a validated 
probabilistic patient-linking algorithm that 
uses patient demographics (name, surname, 
date of birth, etc.) for linking test records to 
unique individuals.[19]
Study outcomes and analysis
The analysis evaluated proportions of women 
who received a VL test during the antenatal 
period, at delivery and within 9 months 
postpartum, expressed as percentages. 
Eligible VLs analysed included any VL 
performed within 9 months before and after 
delivery. Proportions of pregnant WLHIV 
with a documented VL and proportions of 
VL suppression during the antenatal period, 
at delivery and postpartum were calculated. 
Analyses were stratified by: (i) receipt of 
a PoC HIV VL result prior to discharge 
from hospital or not, to determine the 
impact of PoC HIV VL testing on the rate 
of retention postpartum; and (ii) maternal 
VL ≥50 copies/mL v. <50 copies/mL at the 
time of delivery. Pearson’s χ2 test was used 
to test for associations between categorical 
variables, and Fischer’s exact test in the case 
of sparse data. Ethics approval for the study 
was obtained from the Human Research 
Ethics Committee of the University of the 
Witwatersrand (ref. no. M1711115) and the 
Faculty of Health Sciences Research Ethics 
Committee of the University of Pretoria (ref. 
no. 50/2018).
Results
A total of 4 989 pregnant WLHIV received 
PoC HIV VL testing at the time of delivery 
from the four tertiary obstetric units between 
June 2018 and February 2020. Among these, 
3 671 women (73.6%) received their PoC 
HIV VL result prior to discharge from the 
hospital and 1 318 (26.4%) did not. The 
median (interquartile range) maternal age 
was 31.1 (26.6 - 35.6) years (Table 1). A total 
of 917 women (18.4%) had a documented 
VL during the antenatal period, of whom 
335 (36.5%) had a VL ≥50 copies/mL and 
165 (18.0%) a VL ≥1 000 copies/mL (Fig. 1). 
At delivery, 1 911 women (38.3%) had a 
VL ≥50 copies/mL and 1 028 (20.6%) a VL 
≥1 000 copies/mL. A total of 627 women 
(12.6%) had a documented VL within 
9 months postpartum, of whom 234 (37.3%) 
had a VL ≥50 copies/mL and 93 (14.8%) a VL 
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Figure 1. Compliance of VL testing and rates of suppression amongst pregnant and postpartum women living with HIV amongst the cohort. 
Abbreviation: PoC point-of-care, VL viral load in copies/mL 
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Fig. 1. VL testing compliance and rates of suppression among pregnant and postpartum women living 
with HIV in the cohort. (VL = viral load (copies/mL); PoC = point-of-care.) 
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documented VL during the antenatal 
period v. those without were more 
likely to: (i) have a VL <50 copies/mL 
at delivery (n=652 (71.1%) v. n=2 426 
(59.6%); p<0.001) and (ii)  have a 
documented VL postpartum (n=216 
(23.6%) v. n=411 (10.1%); p<0.001). 
However, VL suppression post–
partum was not associated with 
having a VL performed during the 
antenatal period (p=0.478). Overall, 
216 (4.3%) of 4 989 women received 
VL monitoring during the antenatal 
period, at delivery and within 
9 months postpartum.
Receipt of a PoC VL result 
before discharge from the hospital 
was associated with having a VL 
test performed within 9 months 
postpartum. However, the associa-
tion did not reach statistical 
significance (p=0.055) (Table 1). A 
significant proportion of younger 
women (age <25 years) had a 
VL ≥50 copies/mL at the time of 
delivery (Table 1). When compared 
with women with a VL <50 copies/
mL at the time of delivery, women 
with a VL ≥50 copies/mL had fewer 
VLs during the antenatal period 
(265/1 911 (13.8%) v. 652/3 078 
(21.2); p=0.001) and tended to have 
unsuppressed VLs if they had a VL 
during the antenatal period (VL 
≥50 copies/mL for 220/265 women 
(83.0%) v. 115/652 (17.6%); p<0.001) 
(Fig. 1). Rates of postpartum VL 
monitoring were similar between 
the two groups at 251 (13.1%) for 
women with a VL ≥50 copies/mL at 
the time of delivery and 376 (12.2%) 
for women with a VL <50 copies/
mL (p=0.341). However, women 
with a VL ≥50 copies/mL at the 
time of delivery were more likely to 
remain unsuppressed at postpartum 
follow-up than women with a VL 
<50 copies/mL (Fig. 1).
Discussion
We present findings from a review of 
compliance with national VL testing 
guidelines and suppression rates 
during the antenatal and post partum 
periods in Gauteng Province. Fewer 
than 20% of pregnant WLHIV had 
evidence of VL monitoring during 
the antenatal period, with 37% of 
these women having a VL ≥50 copies/
mL prior to delivery. At delivery, 38% 
and 21% of the women had a VL ≥50 
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Overall, the rate of VL monitoring within 9 months postpartum was 
13%, and 37% of women with a VL test within 9 months postpartum 
had a VL ≥50 copies/mL. Women with evidence of VL monitoring 
during the antenatal period were more likely to be virally suppressed 
at delivery and to receive VL monitoring during the postpartum 
period. We observed that a significant proportion of women aged 
<25 years had VLs ≥50 copies/mL at delivery, and that women with a 
VL ≥50 copies/mL at delivery were less likely to be virally suppressed 
at postpartum follow-up than women with a VL <50 copies/mL 
at delivery. Since similar proportions of VLs ≥50 copies/mL were 
observed during the antenatal period (37%), at delivery (38%) and 
within 9 months postpartum (37%), the findings show that a similar 
proportion of women are transitioning the care continuum with 
unsuppressed VLs. In that case, the programme is failing to identify 
distinct groups of women with specific needs that require targeted 
packages of care for maternal VL suppression. However, VL data 
were too few to determine the proportion of women consistently 
unsuppressed at all three time points.
Elimination of MTCT requires sustained maternal VL suppression 
from conception through pregnancy to the end of the breastfeeding 
period. Over 80% of women in our cohort had no evidence of VL 
monitoring during the antenatal period. Given the small window of 
opportunity for intervention between detecting a high maternal VL 
during the antenatal period and time of delivery, it is not surprising 
that 40% of these women had a VL ≥50 copies/mL at delivery. These 
findings speak to the need for improved implementation of frequent 
maternal VL monitoring and rapid reaction to elevated maternal 
VLs during pregnancy and the postpartum period. SA already has 
a robust policy framework that provides for optimal monitoring of 
maternal VLs during pregnancy. What is required are systems for 
improving clinical management of pregnant and postpartum WLHIV 
within the PMTCT programme, including PoC VL testing.[15] PoC VL 
utilisation varied across our study sites, as previously reported,[15] and 
these data show that approximately one in three women who received 
a PoC VL test at delivery did not receive their result prior to discharge 
from the hospital, suggesting suboptimal utilisation. Nonetheless, 
higher proportions of VL monitoring during the postpartum period 
were seen in women who received their delivery PoC HIV VL result 
prior to discharge from the hospital than in those who did not. 
Although the difference was not clinically relevant (11% v. 13%), the 
finding demonstrated the potential of PoC VL testing in improving 
maternal VL testing and subsequent retention in care postpartum in 
routine settings. This observed potential benefit of PoC VL testing 
is particularly important in the current context of very low maternal 
VL testing coverage within the national PMTCT programme, such 
that any intervention that improves VL testing coverage is welcome. 
However, further research is required to explore this association, as 
findings may be biased by underlying health system and patient-level 
factors that were beyond the scope of this study.
Evidence from various studies shows that ~30 - 37% of women 
delivering in the public sector have VLs ≥50 copies/mL at the time 
of delivery.[9-11] We present similar findings for maternal viraemia 
at delivery and within 9 months postpartum. These proportions 
are unacceptably high if the programme is in pursuit of eMTCT, 
especially considering recommendations for extended breastfeeding 
for 2 years postpartum. We found that women who had unsuppressed 
VLs at the time of delivery continued to be unsuppressed during the 
postpartum period. Even more concerning was the observed high 
rate of absent VL monitoring within 9 months postpartum in the 
cohort. This lack places HIV-exposed infants at an increased risk of 
MTCT during breastfeeding.[20-22] Poor monitoring of maternal VLs 
during the postpartum period undermines the benefits of high ART 
coverage prior to delivery by compounding the risk of MTCT in the 
postnatal period. These findings emphasise the need for ongoing 
patient support and improved systems for monitoring patient care 
during pregnancy and the postpartum period in order to achieve 
eMTCT. Until clinical databases can assume this role, routine near-
real-time surveillance of maternal VLs during pregnancy, delivery 
and the postpartum period using the NHLS laboratory database can 
fast-track attainment of eMTCT and the third 90 in this population. 
The revised PMTCT guidelines of 2019 make provision for accurate, 
national surveillance of maternal VLs during pregnancy, at delivery 
and during the postpartum period by introducing the electronic gate-
keeping (EGK) codes C#PMTCT and C#DELIVERY to distinguish 
maternal VL testing at these three time points.[5] The EGK codes are 
meant to be captured on standard laboratory requisition forms for 
specimens submitted to and processed by the NHLS. As with other 
policy recommendations, the success of this initiative depends on 
uptake and implementation by stakeholders.
At patient level, investing in patient support services may 
sensitise mothers to the importance of VL monitoring and empower 
them to take charge of their own health and healthcare, for example 
young mothers and women who are struggling with adherence to 
treatment. The success of the PMTCT programme to date is largely 
attributable to implementation of broad-based and programme-
level interventions. These interventions were necessary and are 
still relevant. However, achieving eMTCT requires a further shift 
towards focusing on case management during pregnancy and 
the postpartum period. Poor case management may explain the 
constant figure of ~37% of women who remain unsuppressed 
throughout the continuum of care in this study. These are probably 
women with specific needs that are not addressed by programme-
level interventions and require extra services. While this approach 
may be time and resource intensive, the PMTCT programme 
can leverage on services provided by ‘MomConnect’ and the 
community healthcare worker programme to address such needs. [23] 
MomConnect is a mobile phone-based health initiative of the 
SA National Department of Health that sends targeted health 
promotion messages to pregnant women (regardless of HIV status) 
accessing ANC in the public health sector. The targeted health 
messages aim at improving both maternal and infant health.[23] 
Subscription to the service is on a voluntary basis and is free of 
charge.
Study limitations
Interpretation of our findings requires consideration of certain 
limitations. We relied on the national laboratory database for VL 
testing patterns throughout the continuum of PMTCT care for the 
study cohort. However, the laboratory database is not a clinical 
longitudinal cohort management system. The VL testing cascade 
generated from laboratory data is based on availability of VL 
testing according to HIV monitoring guidelines. Therefore, some 
women may be in care but not receiving appropriate HIV testing. In 
addition, the laboratory database may be inaccurate for longitudinal 
cohort monitoring as, in the absence of a unique identifier, record 
linkage relies on probabilistic matching of patient demographic 
information. Therefore, some VL results may not have been linked 
to study participants as a result of inconsistent documentation of 
demographics (for example due to data capturing error and/or 
surname changes due to marriage), which would cause the patient-
linking algorithm to fail to link VL results belonging to the same 
patient. Suboptimal linkage of VL results is particularly worth noting 
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considering that pregnant women often attend multiple facilities 
during the antenatal, delivery and postpartum periods,[24] and each 
facility may capture their personal identifiers differently. However, 
a manual search for longitudinal VL test results for 200 randomly 
selected participants was performed from the Laboratory Information 
System. The manual search did not yield additional VL data to results 
obtained from the patient-linking algorithm, suggesting reasonable 
performance of the linking algorithm in finding most of the HIV 
VLs performed on each patient and thereby validating the study 
findings. However, the use of markers specific for maternal VL 
monitoring during pregnancy and the breastfeeding period, such 
as the recommended EGK codes, is anticipated to provide accurate 
surveillance data from the laboratory database in the near future.
Another limitation is the lack of clinical information for study 
participants. Data on maternal ART status during the antenatal period 
were not available to the study to determine timing of the first VL 
and or the impact of ART duration on maternal viraemia during the 
antenatal and postpartum periods. Lastly, considering the low maternal 
VL testing coverage during both these periods, testing may have been 
biased towards unsuppressed women, which may explain why women 
with unsuppressed VLs during pregnancy tended to be unsuppressed 
during the postpartum period. Furthermore, the few VL data in this 
study limited a longitudinal analysis of maternal VL evolution.
Conclusions
Fewer than 5% of WLHIV enrolled in this study received VL 
monitoring during the antenatal and postpartum periods according 
to national guidelines. Approximately one-fifth of women had 
evidence of VL monitoring during the antenatal period. WLHIV 
who did not have VL monitoring during the antenatal period were 
more likely to be virally unsuppressed at delivery and receive no 
postpartum VL monitoring. Women with a high VL at delivery 
were more likely to remain virally unsuppressed postpartum. These 
results emphasise the need for closer monitoring of and urgency in 
responding to elevated maternal VL during pregnancy, at delivery 
and postpartum for the attainment of eMTCT in SA.
Declaration. The research for this study was done in partial fulfilment of 
the requirements for FM’s PhD in Public Health at the University of the 
Witwatersrand.
Acknowledgements. The authors acknowledge the NHLS CDW for 
providing laboratory test data.
Author contributions. GGS, FM and AHM conceived the study design 
and selected indicators for analysis. GGS and FM acquired the data. FM, 
AHM, TK and GGS analysed/interpreted the data. FM and AHM wrote 
the article. TK and GGS provided critical revision and final approval.
Funding. The authors acknowledge financial support for the study from 
the ELMA Foundation and Clinton Health Access Initiative (CHAI)/
UNITAID (project ID CHSOAFHLSTP3).
Conflicts of interest. None.
1. Mandelbrot L, Tubiana R, Le Chenadec J, et al. No perinatal HIV-1 transmission from women with 
effective antiretroviral therapy starting before conception. Clin Infect Dis 2015;61(11):1715-1725. 
http://doi.org/10.1093/cid/civ578
2. Myer L, Essajee S, Broyles LN, et al. Pregnant and breastfeeding women: A priority population for HIV 
viral load monitoring. PloS ONE 2017;14(8):e1002375. https://doi.org/10.1371/journal.pmed.1002375
3. Tubiana R, le Chenadec J, Rouzioux C, et al. Factors associated with mother-to-child transmission 
of HIV-1 despite maternal viral load <500 copies/ml at delivery: A case control study nested in 
the French perinatal cohort (EPF-ANRS CO1). Clin Infect Dis 2010;50(4):585-596. https://doi.
org/10.1086/650005
4. National Department of Health, South Africa. National Consolidated Guidelines for the Prevention 
of Mother-to-Child Transmission of HIV (PMTCT) and the Management of HIV in Children, 
Adolescents and Adults. 2015. http://www.sahivsoc.org/Files/ART%20Guidelines%2015052015.pdf 
(accessed 15 July 2020).
5. Wessels J, Sherman G, Bramford L, et al. The updated South African national guidelines for the 
prevention of mother to child transmission of communicable infections (2019). S Afr J HIV Med 
2020;21(1):a1079. https://doi.org/10.4102/sajhivmed.v21i1.1079
6. Moyo F, Mazanderani AH, Bhardwaj S, et al. Near-real-time tracking of gaps in the prevention of 
mother-to-child transmission of HIV in three districts of KwaZulu-Natal Province, South Africa. S Afr 
Med J 2018;108(4):319-324. https://doi.org/10.7196/SAMJ.2018.v108i4.12630
7. Phillips T, Thebus E, Bekker L-G, et al. Disengagement of HIV-positive pregnant and postpartum 
women from antiretroviral therapy services: A cohort study. J Int AIDS Soc 2014;17(1):19242. https://
doi.org/10.7448/IAS.17.1.19242
8. Nachega JB, Uthman O, Anderson J, et al. Adherence to antiretroviral therapy during and after 
pregnancy in low-income, middle-income, and high-income countries: A systematic review and 
metaanalysis. AIDS 2012;26(16):2039-2052. https://doi.org/10.1097/QAD.0b013e328359590f
9. Myer L, Dunning L, Lesosky M, et al. Frequency of viremic episodes in HIV-infected women initiating 
antiretroviral therapy during pregnancy: A cohort study. Clin Infect Dis 2017;64(4):422-427. https://
doi.org/10.1093/cid/ciw792
10. Moyo F, Haeri Mazanderani A, Murray T, et al. Characterizing viral load burden among HIV-
infected women around the time of delivery: Findings from four tertiary obstetric units in 
Gauteng, South Africa. J Acquir Immune Defic Syndr 2020;83(4):390-396. http://doi.org/10.1097/
QAI.0000000000002267
11. Woldesenbet SA, Kufa T, Lombard C, et al. The 2017 National Antenatal Sentinel HIV Survey key 
findings, South Africa. National Department of Health, July 2019. https://www.researchgate.net/
publication/334883856_The_2017_National_Antenatal_Sentinel_HIV_Survey_Key_Findings_
South_Africa (accessed 16 March 2021).
12. Woldesenbet SA, Kufa T, Barron P, et al. Viral suppression and factors associated with failure to achieve 
viral suppression among pregnant women in South Africa. AIDS 2020;34(4):589-797. https://doi.
org/10.1097/QAD.0000000000002457
13. World Health Organization. Global Guidance on Criteria and Processes for Validation: Elimination of 
Mother-to-Child Transmission (EMTCT) of HIV and Syphilis. Geneva: WHO, 2014. http://apps.who.
int/iris/bitstream/10665/112858/1/9789241505888_eng.pdf?ua=1&ua=1 (accessed 16 May 2020).
14. Joint United Nations Programme on HIV and AIDS (UNAIDS). 90-90-90: An ambitious treatment 
target to help end the AIDS epidemic. October 2014. https://www.unaids.org/sites/default/files/
media_asset/90-90-90_en.pdf (accessed 4 February 2020).
15. Kufa T, Haeri Mazanderani A, Sherman GG, et al. Point-of-care HIV maternal viral load and 
early infant diagnosis testing around time of delivery at tertiary obstetric units in South Africa: A 
prospective study of coverage, results return and turnaround times. J Int AIDS Soc 2020;23:e25487. 
https://doi.org/10.10.1002/jia2.25487
16. Drain PK, Dorward J, Violette LR, et al. Point-of-care HIV viral load testing combined with task shifting 
improve treatment outcomes (STREAM): Findings from an open-label, non-inferiority, randomised 
controlled trial. Lancet HIV 2020;7(4):e229-e237. https://doi.org/10.1016/s2352-3018(19)30402-3
17. ClinicalTrials.gov, US National Library of Medicine. Impact of point-of-care (POC) viral load 
(VL) testing on ensuring appropriate management of viremia during pregnancy to prevent vertical 
transmission: An observational difference-in-difference cohort study, 19th August 2019. Identifier 
NCT00287391. https://clinicaltrials.gov/ct2/show/study/NCT04048629 (accessed 15 May 2020).
18. Moyo S, Mohammed T, Wirth KE, et al. Point-of-care Cepheid Xpert HIV-1 viral load test in rural 
African communities is feasible and reliable. J Clin Microbiol 2016;54(12):3050-3055. https://doi.
org/10.1128/JCM.01594-16
19. Bassett IV, Huang M, Cloete C, et al. Assessing the completeness and accuracy of South African 
National Laboratory CD4 and viral load data: A cross-sectional study. BMJ Open 2018;8:e021506. 
https://doi.org/10.1136/bmjopen-2018-021506
20. Chetty T, Newell M-L, Thorne C, et al. Viraemia before, during and after pregnancy in HIV-infected 
women on antiretroviral therapy in rural KwaZulu-Natal, South Africa, 2010 - 2015. Trop Med Int 
Health 2018;23(1):79-91. http://doi.org/10.1111/tmi.13001
21. Dinh T-H, Delaney KP, Goga A, et al. Impact of maternal HIV seroconversion during pregnancy on 
early mother to child transmission of HIV (MTCT) measured at 4 - 8 weeks postpartum in South 
Africa 2011 - 2012: A national population-based evaluation. PloS ONE 2015;10(5):e0125525. https://
doi.org/10.1371/journal.pone.0125525
22. Patel K, Karalius B, Powis K, et al. Trends in post-partum viral load among women living with perinatal 
HIV infection in the USA: A prospective cohort study. Lancet HIV 2019;7(3)e184-e192. https://doi.
org/10.1016/S2352-3018(19)30339-X
23. National Department of Health, South Africa. MomConnect. http://www.health.gov.za/momconnect/# 
(accessed 16 March 2021).
24. Clouse K, Pettifor A, Shearer K, et al. Loss to follow-up before and after delivery among women testing 
HIV positive during pregnancy in Johannesburg, South Africa. Trop Med Int Health 2013;18(4):451-
460. http://doi.org/10.1111/tmi.12072
Accepted 3 December 2020.
